Editas Medicine: CRISPR technology with great potential
- Editas Medicine has entered into a license agreement with Vertex Pharmaceuticals for the development of CRISPR/Cas9-based therapies for Duchenne muscular dystrophy.
- Editas Medicine has a strong pipeline portfolio with several promising candidates in clinical development.
- Conclusion: Editas Medicine is a good buy for investors interested in the future of CRISPR technology.